Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010 (2010), Article ID 320624, 12 pages
http://dx.doi.org/10.1155/2010/320624
Review Article

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Kliniken Essen Süd, Evangelisches Krankenhaus Essen-Werden gGmbH, Pattbergstraβe 1-3, 45239 Essen, Germany

Received 25 August 2010; Revised 12 October 2010; Accepted 18 October 2010

Academic Editor: Brian Bolwell

Copyright © 2010 Peter Reimer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ascani, P. L. Zinzani, and P. L. Zinzani, “Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification,” Annals of Oncology, vol. 8, no. 6, pp. 583–592, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. J. O. Armitage, “A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma,” Blood, vol. 89, no. 11, pp. 3909–3918, 1997. View at Google Scholar · View at Scopus
  3. T. Rüdiger, D. D. Weisenburger, and D. D. Weisenburger, “Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project,” Annals of Oncology, vol. 13, no. 1, pp. 140–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Coiffier, N. Brousse, M. Peuchmaur, F. Berger, C. Gisselbrecht, P. A. Bryon, and J. Diebold, “Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen,” Annals of Oncology, vol. 1, no. 1, pp. 45–50, 1990. View at Google Scholar
  5. J. Vose, J. Armitage, and D. Weisenburger, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. J. O. Armitage, J. M. Vose, and J. M. Vose, “Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 7, no. 12, pp. 1783–1790, 1989. View at Google Scholar · View at Scopus
  7. C. Gisselbrecht, P. Gaulard, and P. Gaulard, “Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA),” Blood, vol. 92, no. 1, pp. 76–82, 1998. View at Google Scholar · View at Scopus
  8. A. Melnyk, A. Rodríguez, W. C. Pugh, and F. Cabannillas, “Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma,” Blood, vol. 89, no. 12, pp. 4514–4520, 1997. View at Google Scholar · View at Scopus
  9. S. M. Lippman, T. P. Miller, C. M. Spier, D. J. Slymen, and T. M. Grogan, “The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype,” Blood, vol. 72, no. 2, pp. 436–441, 1988. View at Google Scholar · View at Scopus
  10. S. M. Ansell, T. M. Habermann, and T. M. Habermann, “Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2296–2301, 1997. View at Google Scholar · View at Scopus
  11. F. Zaja, D. Russo, and D. Russo, “Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome,” Haematologica, vol. 82, no. 2, pp. 171–177, 1997. View at Google Scholar · View at Scopus
  12. R. Sonnen, W.-P. Schmidt, H. Konrad Müller-Hermelink, and N. Schmitz, “The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas,” British Journal of Haematology, vol. 129, no. 3, pp. 366–372, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. Gallamini, C. Stelitano, and C. Stelitano, “Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study,” Blood, vol. 103, no. 7, pp. 2474–2479, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. P. Went, C. Agostinelli, and C. Agostinelli, “Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score,” Journal of Clinical Oncology, vol. 24, no. 16, pp. 2472–2479, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. Rodríguez, E. Conde, and E. Conde, “Tho adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma,” Haematologica, vol. 92, no. 8, pp. 1067–1074, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Dupuis, J.-F. Emile, and J.-F. Emile, “Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study,” Blood, vol. 108, no. 13, pp. 4163–4169, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. R. D. Gascoyne, P. Aoun, and P. Aoun, “Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma,” Blood, vol. 93, no. 11, pp. 3913–3921, 1999. View at Google Scholar · View at Scopus
  18. B. Falini, S. Pileri, and S. Pileri, “ALK+ lymphoma: clinico-pathological findings and outcome,” Blood, vol. 93, no. 8, pp. 2697–2706, 1999. View at Google Scholar · View at Scopus
  19. H. Q. Huang, Y. L. Peng, and Y. L. Peng, “Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen,” Ai Zheng, vol. 23, no. 11, pp. 1443–1447, 2004. View at Google Scholar · View at Scopus
  20. K. Kim, W. S. Kim, and W. S. Kim, “Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification,” European Journal of Cancer, vol. 38, no. 1, pp. 75–81, 2002. View at Google Scholar · View at Scopus
  21. A. López-Guillermo, J. Cid, and J. Cid, “Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification,” Annals of Oncology, vol. 9, no. 8, pp. 849–855, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Vose, C. Peterson, and C. Peterson, “Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas,” Blood, vol. 76, no. 2, pp. 424–431, 1990. View at Google Scholar · View at Scopus
  23. R. Fanin, M. C. Ruiz de Elvira, A. Sperotto, M. Baccarani, and A. Goldstone, “Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT),” Bone Marrow Transplantation, vol. 23, no. 5, pp. 437–442, 1999. View at Google Scholar · View at Scopus
  24. J. Rodríguez, M. Munsell, and M. Munsell, “Impact of high-dose chemotherapy on peripheral T-cell lymphomas,” Journal of Clinical Oncology, vol. 19, no. 17, pp. 3766–3770, 2001. View at Google Scholar · View at Scopus
  25. A. K. Blystad, G. Enblad, and G. Enblad, “High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas,” Bone Marrow Transplantation, vol. 27, no. 7, pp. 711–716, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. K. W. Song, P. Mollee, A. Keating, and M. Crump, “Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype,” British Journal of Haematology, vol. 120, no. 6, pp. 978–985, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Rodríguez, M. D. Caballero, and M. D. Caballero, “High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience,” Annals of Oncology, vol. 14, no. 12, pp. 1768–1775, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Schetelig, S. Fetscher, and S. Fetscher, “Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation,” Haematologica, vol. 88, no. 11, pp. 1272–1278, 2003. View at Google Scholar · View at Scopus
  29. K. W. Zamkoff, M. D. Matulis, A. C. Mehta, M. W. Beaty, R. E. Hutchison, and T. C. Gentile, “High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with reccurent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma,” Bone Marrow Transplantation, vol. 33, no. 6, pp. 635–638, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. E. Jantunen, T. Wiklund, and T. Wiklund, “Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey,” Bone Marrow Transplantation, vol. 33, no. 4, pp. 405–410, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Jagasia, D. Morgan, and D. Morgan, “Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant,” Leukemia and Lymphoma, vol. 45, no. 11, pp. 2261–2267, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. T. Kewalramani, A. D. Zelenetz, and A. D. Zelenetz, “Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma,” British Journal of Haematology, vol. 134, no. 2, pp. 202–207, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. K. Kim, S. Kim, and S. Kim, “High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival,” Annals of Hematology, vol. 86, no. 6, pp. 435–442, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. S. D. Smith, B. J. Bolwell, and B. J. Bolwell, “Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen,” Bone Marrow Transplantation, vol. 40, no. 3, pp. 239–243, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. A. I. Chen, A. McMillan, R. S. Negrin, S. J. Horning, and G. G. Laport, “Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience,” Biology of Blood and Marrow Transplantation, vol. 14, no. 7, pp. 741–747, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. J. Lee, W.-Y. Au, and W.-Y. Au, “Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study,” Biology of Blood and Marrow Transplantation, vol. 14, no. 12, pp. 1356–1364, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. D.-H. Yang, W. S. Kim, and W. S. Kim, “Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome,” Biology of Blood and Marrow Transplantation, vol. 15, no. 1, pp. 118–125, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. Rodríguez, E. Conde, and E. Conde, “Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience,” European Journal of Haematology, vol. 78, no. 4, pp. 290–296, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. J. Rodríguez, E. Conde, and E. Conde, “The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience,” Annals of Oncology, vol. 18, no. 4, pp. 652–657, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. S. Feyler, H. M. Prince, and H. M. Prince, “The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study,” Bone Marrow Transplantation, vol. 40, no. 5, pp. 443–450, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. C. Kyriakou, C. Canals, and C. Canals, “High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome- Lymphoma Working Party of the European Group for blood and marrow transplantation,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. V. Prochazka, E. Faber, and E. Faber, “Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation,” Biomedical Papers, vol. 153, no. 1, pp. 63–66, 2009. View at Google Scholar
  43. A. Numata, T. Miyamoto, and T. Miyamoto, “Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group,” Bone Marrow Transplantation, vol. 45, no. 2, pp. 311–316, 2010. View at Publisher · View at Google Scholar · View at PubMed
  44. N. Mounier, C. Gisselbrecht, and C. Gisselbrecht, “Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2826–2834, 2004. View at Publisher · View at Google Scholar · View at PubMed
  45. M. Nickelsen, M. Ziepert, and M. Ziepert, “High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL),” Annals of Oncology, vol. 20, no. 12, pp. 1977–1984, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. P. Corradini, C. Tarella, and C. Tarella, “Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation,” Leukemia, vol. 20, no. 9, pp. 1533–1538, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. J. Rodríguez, E. Conde, and E. Conde, “Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group,” European Journal of Haematology, vol. 79, no. 1, pp. 32–38, 2007. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Mercadal, J. Briones, and J. Briones, “Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma,” Annals of Oncology, vol. 19, no. 5, pp. 958–963, 2008. View at Publisher · View at Google Scholar · View at PubMed
  49. P. Reimer, T. Rüdiger, and T. Rüdiger, “Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: results of a prospective multicenter study,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 106–113, 2009. View at Publisher · View at Google Scholar · View at PubMed
  50. F. D'Amore, T. Relander, G. Lauritzsen et al., “Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)—a phase II study of the Nordic Lymphoma Group (NLG),” Haematologica, vol. 94, supplement 2, p. 437, 2009. View at Google Scholar
  51. N. Murashige, M. Kami, and M. Kami, “Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms,” British Journal of Haematology, vol. 130, no. 4, pp. 561–567, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. M. Hamadani, F. T. Awan, P. Elder, T. S. Lin, P. Porcu, K. A. Blum, and S. M. Devine, “Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect,” Biology of Blood and Marrow Transplantation, vol. 14, no. 4, pp. 480–483, 2008. View at Publisher · View at Google Scholar · View at PubMed
  53. S. Le Gouill, N. Milpied, and N. Milpied, “Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2264–2271, 2008. View at Publisher · View at Google Scholar · View at PubMed
  54. C. Kyriakou, C. Canals, and C. Canals, “Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 27, no. 24, pp. 3951–3958, 2009. View at Publisher · View at Google Scholar · View at PubMed
  55. P. Corradini, A. Dodero, and A. Dodero, “Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2172–2176, 2004. View at Publisher · View at Google Scholar · View at PubMed
  56. G. G. Wulf, J. Hasenkamp, W. Jung, B. Chapuy, L. Truemper, and B. Glass, “Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma,” Bone Marrow Transplantation, vol. 36, no. 3, pp. 271–273, 2005. View at Publisher · View at Google Scholar · View at PubMed
  57. C. Haioun, E. Lepage, and E. Lepage, “Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'etude des lymphomes de l'adulte study,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 3025–3030, 2000. View at Google Scholar
  58. N. Mounier, D. Simon, C. Haioun, P. Gaulard, C. Gisselbrecht, and I. Khouri, “Impact of high-dose chemotherapy on peripheral T-cell lymphomas,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1426–1427, 2002. View at Google Scholar
  59. C. Gisselbrecht, E. Lepage, and E. Lepage, “Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2472–2479, 2002. View at Publisher · View at Google Scholar
  60. N. Mounier, C. Gisselbrecht, and C. Gisselbrecht, “All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA),” Annals of Oncology, vol. 15, no. 12, pp. 1790–1797, 2004. View at Publisher · View at Google Scholar · View at PubMed
  61. B. S. Sohn, I. Park, and I. Park, “Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma,” Bone Marrow Transplantation, vol. 44, no. 5, pp. 287–293, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. M. P. Escalón, N. S. Liu, Y. Yang, M. Hess, P. L. Walker, T. L. Smith, and N. H. Dang, “Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience,” Cancer, vol. 103, no. 10, pp. 2091–2098, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. N. Schmitz, L. Trumper, M. Ziepert et al., “Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL),” Blood, vol. 166, no. 18, pp. 3418–3425, 2010. View at Google Scholar
  64. L. H. Trümper, K. Hohloch, M. Kloess et al., “CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1) and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL,” Journal of Clinical Oncology, vol. 24, no. 18s, p. 431: abstract 7538, 2006. View at Google Scholar
  65. J. G. Kim, S. K. Sohn, and S. K. Sohn, “Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 129–134, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. A. Gallamini, F. Zaja, and F. Zaja, “Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial,” Blood, vol. 110, no. 7, pp. 2316–2323, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. E. Weidmann, G. Hess, and G. Hess, “A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas,” Leukemia and Lymphoma, vol. 51, no. 3, pp. 447–455, 2010. View at Publisher · View at Google Scholar · View at PubMed
  68. K. C. Weisel, E. Weidmann, I. Anagnostopoulos, L. Kanz, A. Pezzutto, and M. Subklewe, “Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma,” International Journal of Hematology, vol. 88, no. 4, pp. 434–440, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. Van Imhoff, and S. Rosati, “EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma,” Blood, vol. 112, no. 4, pp. 1039–1041, 2008. View at Publisher · View at Google Scholar · View at PubMed